Clinical Characteristics of Inflammatory Choroidal Neovascularization in a Chinese Population

References

• Perentes Y, Tran VT, Sickenberg M, et al. Subretinal neovascular membranes complicating uveitis: frequency, treatments, and visual outcome. Ocul Immunol Inflamm. 2005;13:219–224
   PubMed Web of Science ®Google Scholar
• Cohen SY, Laroche A, Leguen Y, et al. Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996;103:1241–1244
   PubMed Web of Science ®Google Scholar
• Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol. 2004;137:496–503
   PubMed Web of Science ®Google Scholar
• Giovannini A, Amato GP, Mariotti C, et al. OCT imaging of choroidal neovascularisation and its role in the determination of patients' eligibility for surgery. Br J Ophthalmol. 1999;83:438–442
   PubMed Web of Science ®Google Scholar
• Bian ZM, Elner SG, Elner VM. Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res. 2007;84:812–822
   PubMed Web of Science ®Google Scholar
• Cha HS, Bae EK, Koh JH, et al. Tumor necrosis factor-alpha induces vascular endothelial growth factor-C expression in rheumatoid synoviocytes. J Rheumatol. 2007;34:16–19
   PubMed Web of Science ®Google Scholar
• Huang S, Robinson JB, Deguzman A, et al. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 2000;60:5334–5339
   PubMed Web of Science ®Google Scholar
• Shimada H, Yuzawa M, Hirose T, et al. Pathological findings of multifocal choroiditis with panuveitis and punctate inner choroidopathy. Japan J Ophthalmol. 2008;52:282–288
   PubMed Web of Science ®Google Scholar
• Tatar O, Yoeruek E, Szurman P, et al. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol. 2008;126:782–790
   PubMed Web of Science ®Google Scholar
• Neri P, Lettieri M, Fortuna C, et al. Inflammatory choroidal neovascularization. Middle East Afr J Ophthalmol. 2009;16:245–251
   PubMedGoogle Scholar
• Farah ME, Costa RA, Muccioli C, et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 2002;134:137–139
   PubMed Web of Science ®Google Scholar
• Nowilaty SR, Bouhaimed M; Photodynamic Therapy Study G. Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2006;90:982–986
   PubMed Web of Science ®Google Scholar
• Wyhinny GJ, Jackson JL, Jampol LM, et al. Subretinal neovascularization following multiple evanescent white-dot syndrome. Arch Ophthalmol. 1990;108:1384–1385
   PubMed Web of Science ®Google Scholar
• Rouvas AA, Ladas ID, Papakostas TD, et al. Intravitreal ranibizumab in a patient with choroidal neovascularization secondary to multiple evanescent white dot syndrome. Eur J Ophthalmol. 2007;17:996–999
   PubMed Web of Science ®Google Scholar
• Mavrakanas N, Mendrinos E, Tabatabay C, et al. Intravitreal ranibizumab for choroidal neovascularization secondary to acute multifocal posterior placoid pigment epitheliopathy. Acta Ophthalmol. 2010;88:e54–55
   PubMed Web of Science ®Google Scholar
• Bowie EM, Sletten KR, Kayser DL, et al. Acute posterior multifocal placoid pigment epitheliopathy and choroidal neovascularization. Retina. 2005;25:362–364
   PubMed Web of Science ®Google Scholar
• Balaskas K, Ur Rehman S, D'Souza Y. Long-term ranibizumab treatment for choroidal neovascularization secondary to serpiginous choroiditis. Can J Ophthalmol. 2012;47:e15–e17
   PubMed Web of Science ®Google Scholar
• Song MH, Roh YJ. Intravitreal ranibizumab for choroidal neovascularisation in serpiginous choroiditis. Eye. 2009;23:1873–1875
   PubMed Web of Science ®Google Scholar
• Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987;103:234–235
   PubMed Web of Science ®Google Scholar
• Deschenes J, Murray PI, Rao NA, et al. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm. 2008;16:1–2
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516
   PubMed Web of Science ®Google Scholar
• Macular Photocoagulation Study Group. Krypton laser photocoagulation for idiopathic neovascular lesions: results of a randomized clinical trial. Arch Ophthalmol. 1990;108:832–837
   PubMed Web of Science ®Google Scholar
• (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report: treatment of age-related macular degeneration with photodynamic therapy. Arch Ophthalmol. 1999;117:1329–1345
   PubMed Web of Science ®Google Scholar
• Guyer DR, Yannuzzi LA, Slakter JS, et al. Classification of choroidal neovascularization by digital indocyanine green videoangiography. Ophthalmology. 1996;103:2054–2060
   PubMed Web of Science ®Google Scholar
• Chan WM, Lai TY, Lau TT, et al. Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovascularization secondary to punctate inner choroidopathy or of idiopathic origin: one-year results of a prospective series. Retina. 2008;28:71–80
   PubMed Web of Science ®Google Scholar
• Wachtlin J, Heimann H, Behme T, et al. Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefe's Arch Clin Exp Ophthalmol. 2003;241:899–906
   PubMed Web of Science ®Google Scholar
• Mansour AM, Arevalo JF, Ziemssen F, et al. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol. 2009;148:310–6 e312
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Adan A, Berrocal MH, et al. Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months. Retina. 2011;31:353–363
   PubMed Web of Science ®Google Scholar
• Rouvas A, Petrou P, Douvali M, et al. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina. 2011;31:871–879
   PubMed Web of Science ®Google Scholar
• Fung AT, Pal S, Yannuzzi NA, et al. Multifocal Choroiditis without Panuveitis: clinical characteristics and progression. Retina. 2014;34:98–107
   PubMed Web of Science ®Google Scholar
• Zhang X, Wen F, Zuo C, et al. Clinical features of punctate inner choroidopathy in Chinese patients. Retina. 2011;31:1680–1691
   PubMed Web of Science ®Google Scholar
• Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;131:599–606
   PubMed Web of Science ®Google Scholar
• Baxter SL, Pistilli M, Pujari SS, et al. Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol. 2013;156:468–77 e462
   PubMed Web of Science ®Google Scholar
• Zhang X, Zuo C, Li M, et al. Spectral-domain optical coherence tomographic findings at each stage of punctate inner choroidopathy. Ophthalmology. 2013;120:2678–283
   PubMed Web of Science ®Google Scholar
• Brown J Jr, Folk JC, Reddy CV, et al. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology. 1996;103:1100–1105
   PubMed Web of Science ®Google Scholar
• Freund KB, Ho IV, Barbazetto IA, et al. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina. 2008;28:201–211
   PubMed Web of Science ®Google Scholar
• Kotsolis AI, Killian FA, Ladas ID, et al. Fluorescein angiography and optical coherence tomography concordance for choroidal neovascularisation in multifocal choroidtis. Br J Ophthalmol. 2010;94:1506–1508
   PubMed Web of Science ®Google Scholar
• Liu Y, Wen F, Huang S, et al. Subtype lesions of neovascular age-related macular degeneration in Chinese patients. Graefe's Arch Clin Exp Ophthalmol. 2007;245:1441–1445
   PubMed Web of Science ®Google Scholar
• Bottoni F, Tilanus M. The natural history of juxtafoveal and subfoveal choroidal neovascularization in high myopia. Int Ophthalmol. 2001;24:249–255
   PubMedGoogle Scholar
• Lafaut BA, Bartz-Schmidt KU, Vanden Broecke C, et al. Clinicopathological correlation in exudative age related macular degeneration: histological differentiation between classic and occult choroidal neovascularisation. Br J Ophthalmol. 2000;84:239–243
   PubMed Web of Science ®Google Scholar
• O'Connor GR. Factors related to the initiation and recurrence of uveitis. XL Edward Jackson memorial lecture. Am J Ophthalmol. 1983;96:577–599
   PubMed Web of Science ®Google Scholar
• Pauleikhoff D. Neovascular age-related macular degeneration: natural history and treatment outcomes. Retina. 2005;25:1065–1084
   PubMed Web of Science ®Google Scholar
• Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, et al. Early neovascular bridging of choroidal neovascularization after ranibizumab treatment. Graefe's Arch Clin Exp Ophthalmol. 2009;247:1427–1430
   PubMed Web of Science ®Google Scholar
• Olsen TW, Capone A Jr, Sternberg P Jr, et al. Subfoveal choroidal neovascularization in punctate inner choroidopathy: surgical management and pathologic findings. Ophthalmology. 1996;103:2061–2069
   PubMed Web of Science ®Google Scholar
• Blair MP, Apte RS, Miskala PH, et al. Retrospective case series of juxtafoveal choroidal neovascularization treated with photodynamic therapy with verteporfin. Retina. 2004;24:501–506
   PubMed Web of Science ®Google Scholar
• Spaide RF, Sorenson J,Maranan L. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina. 2005;25:685–690
   PubMed Web of Science ®Google Scholar